化浊通络定眩汤联合西药治疗痰瘀阻窍型眩晕症临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R255.3

基金项目:


Clinical Study on Huazhuo Tongluo Dingxuan Decoction Combined with Western Medicine for Vertigo of Phlegm and Blood Stasis Obstructing Orifices Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察化浊通络定眩汤联合西药治疗痰瘀阻窍型眩晕症的临床疗效。方法:选择2020年6月— 2023年6月湖州市吴兴区人民医院/湖州市吴兴区妇幼保健院收治的80例痰瘀阻窍型眩晕症患者,按随机数字 表法分为治疗组和对照组各40例。对照组给予倍他司汀、盐酸异丙嗪治疗,治疗组在对照组基础上加用化浊 通络定眩汤治疗,2组均治疗14 d。比较2组治疗前后中医证候积分、眩晕症状评定量表(DARS) 评分、脑 部(基底、左椎、右椎) 动脉血流速度、红细胞聚集指数、全血高切黏度、血浆黏度、内皮素-1(ET-1)、降 钙素基因相关肽(CGRP) 水平,并评估2组临床疗效及不良反应发生情况。结果:治疗后,治疗组总有效率 95.00%(38/40),高于对照组77.50%(31/40),差异有统计学意义(P<0.05)。治疗后,2组脑部基底、左椎、 右椎动脉血流速度及CGRP水平均较治疗前升高(P<0.05),DARS评分、中医证候积分、红细胞聚集指数、 全血高切黏度、血浆黏度及ET-1水平降低(P<0.05);治疗组各脑部动脉血流速度及CGRP水平高于对照 组(P<0.05),DARS评分、中医证候积分、红细胞聚集指数、全血高切黏度、血浆黏度及ET-1水平低于对照 组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:化浊通络定眩汤联合西药治 疗痰瘀阻窍型眩晕症,能提高患者脑部血流速度,改善血液高凝状态,减轻眩晕症状,临床疗效显著,安全性 较高。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Huazhuo Tongluo Dingxuan Decoction combined with western medicine on vertigo of phlegm and blood stasis obstructing orifices type. Methods: A total of 80 cases of patients with vertigo of phlegm and blood stasis obstructing orifices type,treated in People's Hospital of Wuxing District of Huzhou/Huzhou Maternity & Child Health Care Hospital from June 2020 to June 2023, were selected and divided into the treatment group and the control group according to the random number table method, with 40 cases in each group. The control group was treated with Betahistine and Promethazine Hydrochloride, and the treatment group was additionally treated with Huazhuo Tongluo Dingxuan Decoction based on the treatment of the control group. Both groups were treated for 14 days. The traditional Chinese medicine (TCM) syndrome scores, Dizziness Assessment Rating Scale (DARS) scores, cerebral (basilar, left vertebral, right vertebral) artery blood flow velocity, erythrocyte aggregation index,whole blood high-shear viscosity,plasma viscosity,endothelin-1 (ET-1),and calcitonin gene- related peptide (CGRP) levels in the two groups were compared before and after treatment. Clinical effects and adverse reactions in the two groups were also evaluated. Results:After treatment,the total effective rate was 95.00% (38/40) in the treatment group, higher than that of 77.50% (31/40) in the control group, with a significant difference (P< 0.05). After treatment,both groups showed increased cerebral artery blood flow velocity (basilar,left vertebral,right vertebral) and CGRP levels compared to before treatment (P<0.05), and DARS scores, TCM syndrome scores, erythrocyte aggregation indexes, whole blood high-shear viscosity, plasma viscosity, and ET-1 levels were decreased (P<0.05). The treatment group had higher cerebral artery blood flow velocity and CGRP level than the control group (P<0.05),and lower DARS score,TCM syndrome score,erythrocyte aggregation index,whole blood high-shear viscosity, plasma viscosity, and ET-1 level than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Huazhuo Tongluo Dingxuan Decoction combined with western medicine for vertigo of phlegm and blood stasis obstructing orifices type can improve cerebral blood flow velocity,alleviate hypercoagulable states,and reduce vertigo symptoms,with significant clinical effects and high safety.

    参考文献
    相似文献
    引证文献
引用本文

章元,李靖,庄荣河.化浊通络定眩汤联合西药治疗痰瘀阻窍型眩晕症临床研究[J].新中医,2025,57(5):64-68

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-03-17
  • 出版日期:
文章二维码